Biotech Mergers In 2001 Whet Investor Appetites: Is Gilead Next?
Executive Summary
Gilead Sciences may be the next biotech company to switch from product success story to acquisition target
You may also be interested in...
Genentech Tarceva Trials “On Track” Despite INTACT: Response To Iressa
Genentech and OSI Pharmaceuticals are pointing to the dosing regimen in clinical trials of Tarceva (erlotinib) as one reason that Phase III studies of the EGFR oncologic agent will have a positive outcome despite the negative findings in AstraZeneca's Phase III program for Iressa
Genentech Tarceva Trials “On Track” Despite INTACT: Response To Iressa
Genentech and OSI Pharmaceuticals are pointing to the dosing regimen in clinical trials of Tarceva (erlotinib) as one reason that Phase III studies of the EGFR oncologic agent will have a positive outcome despite the negative findings in AstraZeneca's Phase III program for Iressa
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.